Quantitatively analyzing metathesis catalyst activity and structural features in silica-supported tungsten imido-alkylidene complexes.

A broad series of fully characterized, well-defined silica-supported W metathesis catalysts with the general formula [(≡SiO)W(═NAr)(═CHCMe2R)(X)] (Ar = 2,6-iPr2C6H3 (AriPr), 2,6-Cl2C6H3 (ArCl), 2-CF3C6H4 (ArCF3), and C6F5 (ArF5); X = OC(CF3)3 (OtBuF9), OCMe(CF3)2 (OtBuF6), OtBu, OSi(OtBu)3, 2,5-dimethylpyrrolyl (Me2Pyr) and R = Me or Ph) was prepared by grafting bis-X substituted complexes [W(NAr)(═CHCMe2R)(X)2] on silica partially dehydroxylated at 700 °C (SiO2-(700)), and their activity was evaluated with the goal to obtain detailed structure-activity relationships. Quantitative influence of the ligand set on the activity (turnover frequency, TOF) in self-metathesis of cis-4-nonene was investigated using multivariate linear regression analysis tools. The TOF of these catalysts (activity) can be well predicted from simple steric and electronic parameters of the parent protonated ligands; it is described by the mutual contribution of the NBO charge of the nitrogen or the IR intensity of the symmetric N-H stretch of the ArNH2, corresponding to the imido ligand, together with the Sterimol B5 and pKa of HX, representing the X ligand. This quantitative and predictive structure-activity relationship analysis of well-defined heterogeneous catalysts shows that high activity is associated with the combination of X and NAr ligands of opposite electronic character and paves the way toward rational development of metathesis catalysts.

The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking.

The dopamine D3 receptor (DRD3) has been suggested to be involved in the mechanisms underlying stimulus-controlled drug-seeking behaviour. Ligands acting as DRD3 antagonists (SB 277011-A) or DRD3 partial agonists (BP 897) have shown some promise for reducing the influence of drug-associated cues on motivational behaviour. Here, effects of SB 277011-A and BP 897 were evaluated on cue-induced reinstatement of nicotine-seeking in rats. The effects of BP 897 on nicotine self-administration under a fixed-ratio 5 (FR5) schedule of reinforcement were also evaluated. SB 277011-A (1-10 mg/kg) was able to block cue-induced reinstatement of nicotine-seeking, indicating that DRD3 selective antagonism may be an effective approach to prevent relapse for nicotine. In contrast, BP 897 did not block the cue-induced reinstatement of nicotine-seeking or nicotine-taking under the FR5 schedule. In a control study, rats did not respond to the light stimuli without nicotine delivery, indicating that the responding for the drug-associated cues was induced by the previous pairing of light stimuli with nicotine's effects. These findings validate the role of DRD3 on reactivity to drug-associated stimuli and suggest that the DRD3 antagonist, but perhaps not the DRD3 partial agonist, could be used to prevent relapse in tobacco smokers.

Making "real" molecules in virtual space.

Predicting "realistic" compounds of given chemical reactions with virtual synthesis tools usually requires the manual intervention of experienced chemists in the enumeration phase for the selection of appropriate reactants, assignment of the corresponding reaction sites, and removal of the unlikely products. To automate the virtual synthesis process, we have moved the expertise intensive parts from the compound library design phase to the reaction library design phase. ChemAxon is building an in silico reaction library containing important preparative transformations, where each reaction definition contains a generic transformation scheme and additional rules to handle the various starting compounds according to the corresponding chemo-, regio-, and stereoselectivity issues. Having well designed reaction definitions in hand, our software tool is able to generate synthetically feasible compound libraries with minimal effort in the enumeration phase.